Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase 3 study A...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Main Authors: Dimopoulos, M A, Stewart, A K, Masszi, T, Špička, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D, Mihaylov, G G, Goranova-Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, A, San-Miguel, J, Ludwig, H, Ro, S, Aggarwal, S, Moreau, P, Palumbo, A
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2017
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436074/
https://ncbi.nlm.nih.gov/pubmed/28430175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.31
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares